344 related articles for article (PubMed ID: 33784603)
1. Design, synthesis, and biological evaluation of a novel dual peroxisome proliferator-activated receptor alpha/delta agonist for the treatment of diabetic kidney disease through anti-inflammatory mechanisms.
Liu K; Zhao X; Qi X; Hou DL; Li HB; Gu YH; Xu QL
Eur J Med Chem; 2021 Jun; 218():113388. PubMed ID: 33784603
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of new 1,2,4-oxadiazole based trans- acrylic acid derivatives as potential PPAR-alpha/gamma dual agonist.
Kaur P; Bhat ZR; Bhat S; Kumar R; Kumar R; Tikoo K; Gupta J; Khurana N; Kaur J; Khatik GL
Bioorg Chem; 2020 Jul; 100():103867. PubMed ID: 32353564
[TBL] [Abstract][Full Text] [Related]
3. Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, improves diabetic nephropathy via activating peroxisome proliferator-activated receptor (PPAR)-α/γ and attenuating endoplasmic reticulum stress in rats.
Ge J; Miao JJ; Sun XY; Yu JY
J Ethnopharmacol; 2016 Aug; 189():238-49. PubMed ID: 27224243
[TBL] [Abstract][Full Text] [Related]
4. The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects.
Hanf R; Millatt LJ; Cariou B; Noel B; Rigou G; Delataille P; Daix V; Hum DW; Staels B
Diab Vasc Dis Res; 2014 Nov; 11(6):440-7. PubMed ID: 25212694
[TBL] [Abstract][Full Text] [Related]
5. PPARα/δ dual agonist H11 alleviates diabetic kidney injury by improving the metabolic disorders of tubular epithelial cells.
Ke Q; Xiao Y; Liu D; Shi C; Shen R; Qin S; Jiang L; Yang J; Zhou Y
Biochem Pharmacol; 2024 Apr; 222():116076. PubMed ID: 38387308
[TBL] [Abstract][Full Text] [Related]
6. Potent anti-diabetic effects of MHY908, a newly synthesized PPAR α/γ dual agonist in db/db mice.
Park MH; Park JY; Lee HJ; Kim DH; Park D; Jeong HO; Park CH; Chun P; Moon HR; Chung HY
PLoS One; 2013; 8(11):e78815. PubMed ID: 24244369
[TBL] [Abstract][Full Text] [Related]
7. PPAR dual agonists: are they opening Pandora's Box?
Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
[TBL] [Abstract][Full Text] [Related]
8. Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach.
Ma Y; Wang SQ; Xu WR; Wang RL; Chou KC
PLoS One; 2012; 7(6):e38546. PubMed ID: 22685582
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, docking, in vitro and in vivo antidiabetic activity of pyrazole-based 2,4-thiazolidinedione derivatives as PPAR-γ modulators.
Naim MJ; Alam O; Alam MJ; Shaquiquzzaman M; Alam MM; Naidu VGM
Arch Pharm (Weinheim); 2018 Apr; 351(3-4):e1700223. PubMed ID: 29400412
[TBL] [Abstract][Full Text] [Related]
10. Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.
Rudolph J; Chen L; Majumdar D; Bullock WH; Burns M; Claus T; Dela Cruz FE; Daly M; Ehrgott FJ; Johnson JS; Livingston JN; Schoenleber RW; Shapiro J; Yang L; Tsutsumi M; Ma X
J Med Chem; 2007 Mar; 50(5):984-1000. PubMed ID: 17274610
[TBL] [Abstract][Full Text] [Related]
11. Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches.
Hidalgo-Figueroa S; Ramírez-Espinosa JJ; Estrada-Soto S; Almanza-Pérez JC; Román-Ramos R; Alarcón-Aguilar FJ; Hernández-Rosado JV; Moreno-Díaz H; Díaz-Coutiño D; Navarrete-Vázquez G
Chem Biol Drug Des; 2013 Apr; 81(4):474-83. PubMed ID: 23289972
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of novel sulindac derivatives as partial agonists of PPARγ with potential anti-diabetic efficacy.
Huang F; Zeng Z; Zhang W; Yan Z; Chen J; Yu L; Yang Q; Li Y; Yu H; Chen J; Wu C; Zhang XK; Su Y; Zhou H
Eur J Med Chem; 2021 Oct; 222():113542. PubMed ID: 34118723
[TBL] [Abstract][Full Text] [Related]
13. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Staels B; Rubenstrunk A; Noel B; Rigou G; Delataille P; Millatt LJ; Baron M; Lucas A; Tailleux A; Hum DW; Ratziu V; Cariou B; Hanf R
Hepatology; 2013 Dec; 58(6):1941-52. PubMed ID: 23703580
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents.
Li Z; Hu L; Wang X; Zhou Z; Deng L; Xu Y; Zhang L
Bioorg Chem; 2019 Nov; 92():103254. PubMed ID: 31518760
[TBL] [Abstract][Full Text] [Related]
15. [Design, synthesis, and PPARalpha/gamma agonistic activity of novel tetrahydroisoquinoline derivatives].
Yu R; Zhou YL; Huan Y; Liu Q; Shen ZF; Liu ZZ
Yao Xue Xue Bao; 2011 Mar; 46(3):311-6. PubMed ID: 21626786
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.
Li Z; Zhou Z; Deng F; Li Y; Zhang D; Zhang L
Eur J Med Chem; 2018 Nov; 159():267-276. PubMed ID: 30296685
[TBL] [Abstract][Full Text] [Related]
17. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.
Calkin AC; Giunti S; Jandeleit-Dahm KA; Allen TJ; Cooper ME; Thomas MC
Nephrol Dial Transplant; 2006 Sep; 21(9):2399-405. PubMed ID: 16720596
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile.
Xu Y; Etgen GJ; Broderick CL; Canada E; Gonzalez I; Lamar J; Montrose-Rafizadeh C; Oldham BA; Osborne JJ; Xie C; Shi Q; Winneroski LL; York J; Yumibe N; Zink R; Mantlo N
J Med Chem; 2006 Sep; 49(19):5649-52. PubMed ID: 16970391
[TBL] [Abstract][Full Text] [Related]
19. Nephroprotective effect of Combretum micranthum G. Don in nicotinamide-streptozotocin induced diabetic nephropathy in rats: In-vivo and in-silico experiments.
Kpemissi M; Potârniche AV; Lawson-Evi P; Metowogo K; Melila M; Dramane P; Taulescu M; Chandramohan V; Suhas DS; Puneeth TA; S VK; Vlase L; Andrei S; Eklu-Gadegbeku K; Sevastre B; Veerapur VP
J Ethnopharmacol; 2020 Oct; 261():113133. PubMed ID: 32673708
[TBL] [Abstract][Full Text] [Related]
20. Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome.
Li Z; Ren Q; Zhou Z; Cai Z; Wang B; Han J; Zhang L
Eur J Med Chem; 2021 Dec; 225():113807. PubMed ID: 34455359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
